Anti-EGFR monoclonal antibodies are an important means of targeted therapy for colorectal cancer, mainly used in combination with chemotherapy for patients with wild-type KRAS and NRAS advanced colorectal cancer, which can significantly improve the objective response rate and progression-free survival of patients (Biller and Schrag, 2021). Here, NRAS is linked to colorectal cancer.